Maze Therapeutics (NASDAQ:MAZE) CMO Sells $135,155.82 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,106 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $26.47, for a total transaction of $135,155.82. Following the sale, the chief marketing officer directly owned 14,894 shares in the company, valued at approximately $394,244.18. This represents a 25.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total value of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total value of $436,809.10.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $26.21 on Monday. The stock’s 50-day simple moving average is $28.69 and its 200-day simple moving average is $31.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Equities analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds have recently bought and sold shares of the business. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Maze Therapeutics during the 4th quarter worth about $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the 2nd quarter valued at about $48,000. Finally, Russell Investments Group Ltd. boosted its holdings in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the last quarter.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of research reports. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.